Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Sarcoma 3Sarcoma, Ewing 2Insulin-Like Growth Factor I, Resistance To 2Carcinoma, Non-Small-Cell Lung 2Carcinoid Tumor 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Jaundice 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Sunitinib 3Everolimus 3cabozantinib 2Temozolomide 2sapanisertib 1motesanib diphosphate 1ibrutinib 1ganitumab 1batifiban 1aflibercept 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cryotherapy 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenoma, Islet Cell × ganitumab × Clear all
NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡